Eric Swayze Sells 10,602 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock

by · The Markets Daily

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) EVP Eric Swayze sold 10,602 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $79.18, for a total value of $839,466.36. Following the completion of the transaction, the executive vice president directly owned 21,759 shares in the company, valued at approximately $1,722,877.62. The trade was a 32.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ionis Pharmaceuticals Stock Up 3.6%

Shares of Ionis Pharmaceuticals stock traded up $2.84 on Friday, hitting $81.18. 3,828,233 shares of the company’s stock traded hands, compared to its average volume of 1,762,614. Ionis Pharmaceuticals, Inc. has a 52-week low of $39.37 and a 52-week high of $86.74. The company has a quick ratio of 4.09, a current ratio of 4.10 and a debt-to-equity ratio of 2.75. The stock has a market cap of $13.42 billion, a P/E ratio of -39.22 and a beta of 0.37. The firm’s 50-day moving average is $75.03 and its 200 day moving average is $77.36.

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.29. The company had revenue of $246.09 million during the quarter, compared to analyst estimates of $195.56 million. Ionis Pharmaceuticals had a negative net margin of 30.91% and a negative return on equity of 58.65%. The firm’s revenue for the quarter was up 86.4% compared to the same quarter last year. During the same period last year, the business earned ($0.93) EPS. Equities analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.64 earnings per share for the current year.

Institutional Investors Weigh In On Ionis Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Jain Global LLC boosted its stake in Ionis Pharmaceuticals by 3,037.4% in the third quarter. Jain Global LLC now owns 225,739 shares of the company’s stock valued at $14,768,000 after acquiring an additional 218,544 shares during the period. DAVENPORT & Co LLC raised its position in shares of Ionis Pharmaceuticals by 248.3% during the 4th quarter. DAVENPORT & Co LLC now owns 217,897 shares of the company’s stock worth $17,238,000 after purchasing an additional 155,334 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Ionis Pharmaceuticals by 230.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 878,155 shares of the company’s stock worth $57,449,000 after purchasing an additional 612,362 shares during the period. SG Americas Securities LLC lifted its holdings in shares of Ionis Pharmaceuticals by 548.7% in the 4th quarter. SG Americas Securities LLC now owns 33,409 shares of the company’s stock worth $2,643,000 after purchasing an additional 28,259 shares during the last quarter. Finally, DCF Advisers LLC lifted its holdings in shares of Ionis Pharmaceuticals by 18.2% in the 3rd quarter. DCF Advisers LLC now owns 108,413 shares of the company’s stock worth $7,092,000 after purchasing an additional 16,663 shares during the last quarter. Institutional investors and hedge funds own 93.86% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Raymond James Financial assumed coverage on Ionis Pharmaceuticals in a report on Friday, April 10th. They issued an “outperform” rating and a $104.00 price objective for the company. Royal Bank Of Canada lifted their target price on Ionis Pharmaceuticals from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Thursday, April 30th. Citigroup assumed coverage on Ionis Pharmaceuticals in a report on Monday, May 18th. They issued a “buy” rating and a $115.00 price target for the company. Wall Street Zen raised Ionis Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 2nd. Finally, Morgan Stanley upped their price target on Ionis Pharmaceuticals from $95.00 to $130.00 and gave the company an “overweight” rating in a research report on Tuesday, April 21st. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $102.90.

View Our Latest Stock Report on IONS

Key Headlines Impacting Ionis Pharmaceuticals

Here are the key news stories impacting Ionis Pharmaceuticals this week:

  • Positive Sentiment: Ionis received FDA approval expanding TRYNGOLZA to treat severe hypertriglyceridemia, strengthening the drug’s commercial opportunity and making it the first approved therapy for the condition. Article Title
  • Positive Sentiment: Ionis announced a licensing deal with Recordati for ex-U.S. rights to zilganersen in Alexander disease, which provides upfront and royalty potential while allowing Ionis to keep U.S. commercialization rights. Article Title
  • Positive Sentiment: Leerink Partners raised its price target on Ionis, signaling continued analyst confidence in the company’s pipeline and commercial execution. Article Title
  • Neutral Sentiment: HC Wainwright kept a Buy rating but lowered some 2027 EPS estimates, which is a mild headwind but not a major shift in the firm’s overall view. Article Title

About Ionis Pharmaceuticals

(Get Free Report)

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.

See Also